Skip to content

Magnetic Marker Localization for breast cancer surgery: An exploratory study

Magnetic Marker Localization for breast cancer surgery: An exploratory study - MaMaLoc-2

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON44563
Enrollment
70
Registered
2017-07-18
Start date
2017-10-31
Completion date
Unknown
Last updated
2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer breast carcinoma

Interventions

Subjects will be randomly assigned to either the first (control) or second (intervention) group by means of drawing an envelope. Wire Guided Localization is the current standard of care. With the Ma

Sponsors

Antoni van Leeuwenhoek Ziekenhuis
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: *breast cancer patient *scheduled for breast conserving surgery with localization *aged >=18 years *unifocal tumor *good ultrasound visibility

Exclusion criteria

Exclusion criteria: * Planned MRI in the period between marker placement and surgery * (Expected) time between placement of magnetic marker and surgery * 30 day * Pregnancy

Design outcomes

Primary

MeasureTime frame
Ease of use surgeon (System Usability Scale)

Secondary

MeasureTime frame
* Radiologist satisfaction (SUS) * Retrospective think aloud for surgeon and radiologist after procedure * Tumor-depth on ultrasound and mammography, in mm (skin to lesion) * Surgeon convenience (specific questionnaire) * Operative time in minutes * Delay in OR sheculding/start as a consequence of the localization technology (in minutes) * Intervention only: learning curve assessment * Intervention only: marker migration * Success percentage: no fall-back to ultrasound needed * Specimen weight (g), size (mm), volume (cc) * Dominant tumor size (in mm) * Resection margin status * Histopathological data * Patient reported pain (VAS) * Patien reported convenience (likert)

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)